The Future of Biotechnology Patents: How Judge Bryson’s Dissent in Association for Molecular Pathology v. Myriad Genetics, Inc. Raises Telling Questions

25 Pages Posted: 5 Sep 2012

Date Written: February 17, 2012

Abstract

As technological advancements have grown exponentially over the years, the clarity of patent eligible subject matter standards has become murkier. This Comment seeks to delve into the ever-changing biotechnology industry and the potentially unforeseen effects that may result from the direction different courts are moving. The Comment will focus on a contested issue in the recently decided case Association for Molecular Pathology v. Myriad Genetics, Inc. – a decision containing various analyses of the composition claims of isolated DNA molecules.

Keywords: Intellectual Property, Biotechnology Patents

Suggested Citation

McNally, Caroline, The Future of Biotechnology Patents: How Judge Bryson’s Dissent in Association for Molecular Pathology v. Myriad Genetics, Inc. Raises Telling Questions (February 17, 2012). Available at SSRN: https://ssrn.com/abstract=2142005 or http://dx.doi.org/10.2139/ssrn.2142005

Caroline McNally (Contact Author)

affiliation not provided to SSRN ( email )

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
56
Abstract Views
402
rank
412,893
PlumX Metrics